[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100458923":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":33,"locations":38,"responsibleParty":57,"collaborators":21,"id":60,"slug":21,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":21,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":21,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":21,"overallStatus":41,"whyStopped":21,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Zhongnan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"68Ga-pentixafor and 18F-FDG PET\u002FCT","EXPERIMENTAL","Patients with a high clinical suspicion of, or confirmed newly diagnosed or relapsed hematological malignancies will be recruited. All enrolled patients will undergo both 68Ga-pentixafor and 18F-FDG PET\u002FCT imaging within two weeks.",[13,14],"Drug: 68Ga-pentixafor","Device: PET\u002FCT",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","68Ga-pentixafor","All participants undergo intravenous administration of 68Ga-pentixafor (1.85-3.71 MBq\u002Fkg body weight).",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DEVICE","PET\u002FCT","PET\u002FCT imaging is performed 1 h after intravenous injection of 68Ga-pentixafor.",[9],[28],"Positron Emission Tomography\u002FComputed Tomography",[30],{"name":31,"affiliation":5,"role":32},"Yong He, MD, PhD","PRINCIPAL_INVESTIGATOR",[34],{"name":31,"role":35,"phone":36,"phoneExt":21,"email":37},"CONTACT","+86-27-67812698","vincentheyong@163.com",[39],{"facility":40,"status":41,"city":42,"state":43,"zip":44,"country":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Zhongnan Hospital of Wuhan University","RECRUITING","Wuhan","Hubei","430071","China",{"type":47,"coordinates":48},"Point",[49,50],114.26667,30.58333,{"lat":50,"lon":49},[53,56],{"name":54,"role":35,"phone":55,"phoneExt":21,"email":21},"Lei Zheng","+86-27-67812787",{"name":31,"role":32,"phone":21,"phoneExt":21,"email":21},{"type":32,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":21,"oldOrganization":21},"Yong He","Principal Investigator","100458923",false,"NCT05255926","CXCR4-targeted PET\u002FCT Imaging in Hematological Malignancies","An Exploratory, Open-Label, Single Center Study of CXCR4-targeted PET\u002FCT Imaging for Evaluation of Hematological Malignancies","Inclusion Criteria:\n\n1. Volunteer to participate and sign an informed consent form;\n2. 18 ≤ Age ≤ 90 years;\n3. Patients with highly suspected, or newly diagnosed, or relapsed hematological malignancies;\n4. Willing and able to follow schedule visits, treatment plans and laboratory tests.\n\nExclusion Criteria:\n\n1. pregnancy or breastfeeding;\n2. Allergic to CXCR4-targeted tracers or excipients;\n3. Fasting blood glucose level exceeded 11.0 mmol\u002FL prior to injection of 18F-FDG;\n4. Those who cannot complete PET\u002FCT scan, including inability to keep supine, claustrophobia, radiation phobia, etc.;\n5. Researchers think it is inappropriate to participate in this clinical trial for patients with poor compliance or other unsuitable factors.","ALL","18 Years","90 Years",{"count":70,"type":71},300,"ESTIMATED","INTERVENTIONAL",[74],"NA","Hematological malignancies continue to pose significant clinical challenges due to their high incidence, heterogeneous biology, and substantial mortality. Although 18F-FDG PET\u002FCT remains the most commonly used molecular imaging modality, its limited specificity can result in false-positive or false-negative findings, especially in indolent or low-metabolism subtypes, thereby hampering accurate diagnosis, staging, and therapeutic evaluation. C-X-C chemokine receptor type 4 (CXCR4) is frequently overexpressed in a broad spectrum of hematologic malignancies and correlates with aggressive disease and unfavorable outcomes. CXCR4-targeted molecular imaging using \\^68Ga-pentixafor PET\u002FCT has shown promise for improved disease characterization. This prospective study aims to systematically compare 68Ga-pentixafor PET\u002FCT with 18F-FDG PET\u002FCT in terms of diagnostic performance, staging accuracy, risk stratification, and prognostic relevance in patients with hematological malignancies. Furthermore, the study will incorporate artificial intelligence-based image analysis to enhance lesion detection, automate quantitative assessments, and support personalized clinical decision-making.",[77,24,78],"CXCR4","Hematological Malignancy","2025-06-22",{"date":81,"type":82},"2025-06-26","ACTUAL",{"date":84,"type":82},"2022-03-01",{"date":86,"type":71},"2026-12-31",{"name":5,"class":6},1]